Previous close | 6.56 |
Open | 6.48 |
Bid | 5.86 x 100 |
Ask | 5.90 x 200 |
Day's range | 5.61 - 7.08 |
52-week range | 3.45 - 10.83 |
Volume | |
Avg. volume | 375,229 |
Market cap | 256.983M |
Beta (5Y monthly) | 1.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.51 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 27 Jan 2010 |
1y target est | 13.67 |
AxoGen (AXGN) delivered earnings and revenue surprises of 40% and 1.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up fro
Key Insights Institutions' substantial holdings in AxoGen implies that they have significant influence over the...